Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Gemcitabine + GP-2250|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|GP-2250||GP 2250|GP2250|substance 2250||GP-2250 is an analog of Taurultam that induces reactive oxygen species (ROS) production, potentially resulting in reduced cell viability and proliferation, increased apoptosis, and inhibition of tumor growth (PMID: 28340556).|
|Gemcitabine||Gemzar||Difluorodeoxycytidine Hydrochlorothiazide|LY-188011||Chemotherapy - Antimetabolite 11||Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03854110||Phase Ib/II||Gemcitabine + GP-2250 GP-2250||Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine||Recruiting|